Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Roman

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 5, 2003
Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomasAnna Colomer, Nadina Erill, Montse Verdú, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|December 2, 2005
A novel logistic model based on clinicopathological features predicts microsatellite instability in colorectal carcinomasAnna Colomer, Nadina Erill, August Vidal, et al.
Physiology & Behavior|October 9, 2018
Social isolation impairs active avoidance performance and decreases neurogenesis in the dorsomedial telencephalon of rainbow troutMaria Soledad Ausas, Laura Mazzitelli-Fuentes, Fernanda Ruth Roman, et al.
Virchows Archiv : an International Journal of Pathology|May 25, 2013
ERG expression and prostatic adenocarcinomaMontse Verdu, Isabel Trias, Ruth Roman, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|November 13, 2014
Cross-reactivity of EGFR mutation-specific immunohistochemistry assay in HER2-positive tumorsMontse Verdu, Isabel Trias, Ruth Roman, et al.
Nature Communications|April 20, 2019
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapyJordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, et al.
Journal of Clinical Pathology|August 25, 2021
Reference standards for gene fusion molecular assays on cytological samples: an international validation studyUmberto Malapelle, Francesco Pepe, Pasquale Pisapia, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Applied Immunohistochemistry & Molecular Morphology : AIMM|June 5, 2003
Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomasAnna Colomer, Nadina Erill, Montse Verdú, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|December 2, 2005
A novel logistic model based on clinicopathological features predicts microsatellite instability in colorectal carcinomasAnna Colomer, Nadina Erill, August Vidal, et al.
Physiology & Behavior|October 9, 2018
Social isolation impairs active avoidance performance and decreases neurogenesis in the dorsomedial telencephalon of rainbow troutMaria Soledad Ausas, Laura Mazzitelli-Fuentes, Fernanda Ruth Roman, et al.
Virchows Archiv : an International Journal of Pathology|May 25, 2013
ERG expression and prostatic adenocarcinomaMontse Verdu, Isabel Trias, Ruth Roman, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|November 13, 2014
Cross-reactivity of EGFR mutation-specific immunohistochemistry assay in HER2-positive tumorsMontse Verdu, Isabel Trias, Ruth Roman, et al.
Nature Communications|April 20, 2019
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapyJordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, et al.
Journal of Clinical Pathology|August 25, 2021
Reference standards for gene fusion molecular assays on cytological samples: an international validation studyUmberto Malapelle, Francesco Pepe, Pasquale Pisapia, et al.
Pageof 1